HHS Public Access Author manuscript Author Manuscript
Ophthalmology. Author manuscript; available in PMC 2016 October 01. Published in final edited form as: Ophthalmology. 2015 October ; 122(10): 1987–2001. doi:10.1016/j.ophtha.2015.06.041.
The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis Srishti Kothari1,2,3, C. Stephen Foster1,2,6, Maxwell Pistilli3,4, Teresa L. Liesegang7, Ebenezer Daniel3, H. Nida Sen10, Eric B. Suhler7,10, Jennifer E. Thorne11,12, Douglas A. Jabs11,13,14, Grace A. Levy-Clarke9,15, Robert B. Nussenblatt9, James T. Rosenbaum7,8,16, Scott D. Lawrence17, and John H. Kempen3,4,5 for the SITE Research Group*
Author Manuscript
1The
Author Manuscript
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 2Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts 3Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 4The Center for Preventive Ophthalmology and Biostatistics, The Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania 5Department of Biostatistics and Epidemiology, The Center for Clinical Epidemiology and Biostatistics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 6Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 7Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon 8Department of Medicine, Oregon Health and Science University, Portland, Oregon 9The Laboratory of Immunology, National Eye Institute, Bethesda, Maryland 10Portland Veteran’s Affairs Medical Center, Portland, Oregon 11Department of Epidemiology,
Corresponding Author & Address: John H. Kempen, MD, PhD; Address: Center for Preventive Ophthalmology and Biostatistics; Department of Ophthalmology; University of Pennsylvania; 3535 Market Street, Suite 700; Philadelphia, PA 19104; [email protected]. *The SITE Research Group Credit Roster is available as the Appendix online at http://aaojournal.org Presented at: ARVO, May 4–8, 2014, Orlando, Florida
Author Manuscript
Conflict of interest: The following potential conflicts of interest were reported: C. Stephen Foster serves as a consultant for AbbVie, Alcon Laboratories, Allergan, Inc., Ista Pharmaceuticals, Lux Biosciences, Novartis Pharmaceutical, Bausch & Lomb Surgical and as an equity owner for EyeGate. Jennifer E. Thorne serves a consultant for AbbVie, Gilead and Xoma. Douglas A. Jabs serves on Data and Safety Monitoring committees for Applied Genetic Technologies Corporation and Novartis Pharmaceutical Corporation and as a consultant to Santen, Inc. Grace A. Levy-Clarke was employed by Johnson & Johnson Vision Care. James T. Rosenbaum serves or has served as a consultant for AbbVie, Amgen, Allergan, EMD Serono, Genentech, Lux, Novartis, Regeneron, Sanofi, Santen, UCB, and Xoma and has been involved in clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and Eyegate Pharma. Scott D. Lawrence has received payment for lectures, including service on speakers’ bureaus–Alcon. John H. Kempen serves or has served as a consultant for AbbVie, Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Roche, Sanofi-Pasteur, and Xoma. Contributions: Design and conduct of the study (SK, MP, CSF, JHK); collection, management, analysis and interpretation of the data (all authors); preparation, review, or approval of the manuscript (all authors) Institutional Review Board Approval: The project was conducted in accordance with the principles of the Declaration of Helsinki, with the approval of the governing Institutional Review Boards of each institution, each of which has granted waiver of consent, allowing all living and deceased patients to be included. This article contains additional online-only material. The following should appear online-only: Tables 2, 4, and Appendix. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Kothari et al.
Page 2
Author Manuscript
The Johns Hopkins University Bloomberg School of Public Health, Baltimore Maryland 12Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 13Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York 14Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York 15The Tampa Bay Uveitis Center, Safety Harbor, Florida 16The Devers Eye Institute, Portland, Oregon 17Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States of America
Abstract Purpose—To characterize the risk and risk factors for intraocular pressure (IOP) elevation in pediatric non-infectious uveitis.
Author Manuscript
Design—Multi-center retrospective cohort study. Participants—Nine hundred sixteen children (1593 eyes)
Ophthalmology. Author manuscript; available in PMC 2016 October 01. Published in final edited form as: Ophthalmology. 2015 October ; 122(10): 1987–2001. doi:10.1016/j.ophtha.2015.06.041.
The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis Srishti Kothari1,2,3, C. Stephen Foster1,2,6, Maxwell Pistilli3,4, Teresa L. Liesegang7, Ebenezer Daniel3, H. Nida Sen10, Eric B. Suhler7,10, Jennifer E. Thorne11,12, Douglas A. Jabs11,13,14, Grace A. Levy-Clarke9,15, Robert B. Nussenblatt9, James T. Rosenbaum7,8,16, Scott D. Lawrence17, and John H. Kempen3,4,5 for the SITE Research Group*
Author Manuscript
1The
Author Manuscript
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 2Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts 3Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 4The Center for Preventive Ophthalmology and Biostatistics, The Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania 5Department of Biostatistics and Epidemiology, The Center for Clinical Epidemiology and Biostatistics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 6Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 7Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon 8Department of Medicine, Oregon Health and Science University, Portland, Oregon 9The Laboratory of Immunology, National Eye Institute, Bethesda, Maryland 10Portland Veteran’s Affairs Medical Center, Portland, Oregon 11Department of Epidemiology,
Corresponding Author & Address: John H. Kempen, MD, PhD; Address: Center for Preventive Ophthalmology and Biostatistics; Department of Ophthalmology; University of Pennsylvania; 3535 Market Street, Suite 700; Philadelphia, PA 19104; [email protected]. *The SITE Research Group Credit Roster is available as the Appendix online at http://aaojournal.org Presented at: ARVO, May 4–8, 2014, Orlando, Florida
Author Manuscript
Conflict of interest: The following potential conflicts of interest were reported: C. Stephen Foster serves as a consultant for AbbVie, Alcon Laboratories, Allergan, Inc., Ista Pharmaceuticals, Lux Biosciences, Novartis Pharmaceutical, Bausch & Lomb Surgical and as an equity owner for EyeGate. Jennifer E. Thorne serves a consultant for AbbVie, Gilead and Xoma. Douglas A. Jabs serves on Data and Safety Monitoring committees for Applied Genetic Technologies Corporation and Novartis Pharmaceutical Corporation and as a consultant to Santen, Inc. Grace A. Levy-Clarke was employed by Johnson & Johnson Vision Care. James T. Rosenbaum serves or has served as a consultant for AbbVie, Amgen, Allergan, EMD Serono, Genentech, Lux, Novartis, Regeneron, Sanofi, Santen, UCB, and Xoma and has been involved in clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and Eyegate Pharma. Scott D. Lawrence has received payment for lectures, including service on speakers’ bureaus–Alcon. John H. Kempen serves or has served as a consultant for AbbVie, Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Roche, Sanofi-Pasteur, and Xoma. Contributions: Design and conduct of the study (SK, MP, CSF, JHK); collection, management, analysis and interpretation of the data (all authors); preparation, review, or approval of the manuscript (all authors) Institutional Review Board Approval: The project was conducted in accordance with the principles of the Declaration of Helsinki, with the approval of the governing Institutional Review Boards of each institution, each of which has granted waiver of consent, allowing all living and deceased patients to be included. This article contains additional online-only material. The following should appear online-only: Tables 2, 4, and Appendix. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Kothari et al.
Page 2
Author Manuscript
The Johns Hopkins University Bloomberg School of Public Health, Baltimore Maryland 12Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 13Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York 14Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York 15The Tampa Bay Uveitis Center, Safety Harbor, Florida 16The Devers Eye Institute, Portland, Oregon 17Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States of America
Abstract Purpose—To characterize the risk and risk factors for intraocular pressure (IOP) elevation in pediatric non-infectious uveitis.
Author Manuscript
Design—Multi-center retrospective cohort study. Participants—Nine hundred sixteen children (1593 eyes)
